Quantify Research‘s own Konstantin Macheridis shares insights in a newly published article on access to treatments for rare diseases. The Swedish HTA-agency Tandvårds- och läkemedelsförmånsverket, TLV has undertaken development work to increase access to orphan drugs through the national reimbursement system. The hope is that it will lead to improved access to orphan drugs – but to what extent remains uncertain.
👉 Read the article (in Swedish): Here
